Teva Pharmaceutical Industries (TEVA) Stock Price, News & Analysis

Company Overview

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company develops, manufactures and distributes generic medicines, specialty pharmaceuticals, active pharmaceutical ingredients and biosimilars.

Teva’s portfolio includes medicines for conditions affecting the central nervous system, respiratory system and other therapeutic areas. Its branded and specialty products include treatments such as Copaxone for multiple sclerosis, Austedo for movement disorders, Ajovy for migraine prevention and Uzedy for schizophrenia. The company also supplies a broad range of generic medicines in multiple dosage forms.

Teva serves patients, healthcare providers and pharmaceutical partners in markets across North America, Europe and other international regions. The company is led by President and Chief Executive Officer Richard Francis, who assumed the role in 2023.

Key Stats

• Today's Range: $40.71 to $41.87
• 50-Day Range: $34.76 to $41.22
• 52-Week Range: $18.83 to $42.02
• Volume: 10.27 million shs
• Average Volume: 6.00 million shs
• Market Capitalization: $47.58 billion
• P/E Ratio: 68.05
• Dividend Yield: N/A
• Price Target: $45.50
• Consensus Rating: Moderate Buy

Teva Pharmaceutical Industries Stock Analysis - MarketRank™

Teva Pharmaceutical Industries scored higher than 89% of companies evaluated by MarketBeat, and ranked 57th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Teva Pharmaceutical Industries has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on no strong buy ratings, 12 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Teva Pharmaceutical Industries has a consensus price target of $45.50, representing about 11.4% upside from its current price of $40.83.

Amount of Analyst Coverage

Teva Pharmaceutical Industries has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 52.00%

Earnings Growth

Earnings for Teva Pharmaceutical Industries are expected to grow by 52.00% in the coming year, from $2.00 to $3.04 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Teva Pharmaceutical Industries is 68.05, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 40.79.

Price to Earnings Ratio vs. Sector

The P/E ratio of Teva Pharmaceutical Industries is 68.05, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 195.97.

Price to Earnings Growth Ratio

Teva Pharmaceutical Industries has a PEG Ratio of 3.83. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Teva Pharmaceutical Industries has a P/B Ratio of 5.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.58% of the float of Teva Pharmaceutical Industries has been sold short.

Short Interest Ratio / Days to Cover

Teva Pharmaceutical Industries has a short interest ratio ("days to cover") of 5.4.

Change versus previous month

Short interest in Teva Pharmaceutical Industries has recently decreased by 5.18%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Teva Pharmaceutical Industries does not currently pay a dividend.

Dividend Growth

Teva Pharmaceutical Industries does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Teva Pharmaceutical Industries is 168.50%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on earnings estimates, Teva Pharmaceutical Industries will have a dividend payout ratio of 33.26% next year. This indicates that Teva Pharmaceutical Industries will be able to sustain or increase its dividend.

News and Social Media

• Score: 4.3 / 5
• News Sentiment: 0.88

News Sentiment

Teva Pharmaceutical Industries has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 23 news articles for Teva Pharmaceutical Industries this week, compared to 9 articles on an average week.

Search Interest

11 people have searched for TEVA on MarketBeat in the last 30 days. This is an increase of 120% compared to the previous 30 days.

MarketBeat Follows

6 people have added Teva Pharmaceutical Industries to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Teva Pharmaceutical Industries insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,644,285.00 in company stock.

Percentage Held by Insiders

0.54% of the stock of Teva Pharmaceutical Industries is held by insiders.

Percentage Held by Institutions

54.05% of the stock of Teva Pharmaceutical Industries is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 6/30/2026
• Today: 10/14/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:TEVA
• CIK: 818686
• Web: www.tevapharm.com
• Phone: (723) 914-8213
• Fax: 972-3923-4050
• Employees: 33,950
• Year Founded: 1901

Price Target and Rating

• Average Price Target for Teva Pharmaceutical Industries: $45.50
• High Price Target: $55.00
• Low Price Target: $40.00
• Potential Upside/Downside: +11.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.92
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.60
• Trailing P/E Ratio: 68.05
• Forward P/E Ratio: 20.41
• P/E Growth: 3.83
• Net Income: $1.41 billion
• Net Margins: 4.08%
• Pretax Margin: 4.09%
• Return on Equity: 32.64%
• Return on Assets: 6.34%

Debt

• Debt-to-Equity Ratio: 1.56
• Current Ratio: 0.88
• Quick Ratio: 0.67

Sales & Book Value

• Annual Sales: $17.31 billion
• Price / Sales: 2.75
• Cash Flow: $3.69 per share
• Price / Cash Flow: 11.06
• Book Value: $6.88 per share
• Price / Book: 5.93

Miscellaneous

• Outstanding Shares: 1,165,296,000
• Free Float: 1,159,003,000
• Market Cap: $47.58 billion
• Optionable: Optionable
• Beta: 0.89